Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.

CONCLUSIONS: Our work provides experimental evidence on the association of 6PGD with poor prognosis in breast cancer and suggests that 6PGD inhibition may represent a potential therapeutic strategy to augment chemotherapy efficacy in breast cancer. PMID: 29340974 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Oncol Source Type: research